← Back to Screener
US Stock Screener
HomeScreensNewsWatchlist
...
HomeStocksUTHRPrice Target
OverviewPriceRevenueEarningsP/ERatiosDividendTargets

United Therapeutics Corporation (UTHR) Price Target Analysis

Wall Street analyst price targets, ratings consensus & upside potential · Updated Feb 28, 2026

Current Price
$503.90
Market reference
Price Target
$563.17
+11.8% Upside
Target Range
$447.00 — $645.00
Moderate consensus
Analyst Rating
Buy
30 analysts
Forward P/E16.9x
Trailing P/E18.1x
Forward PEG0.88
Implied Growth+7.0%
Median Target$581.00
Analyst Spread35.2%

UTHR trades near analyst consensus with +11.8% potential upside. Limited near-term catalysts may be priced in at current levels.

Price Forecast (1 Year)

Last 12 months price action with 12-month analyst target path

Current$503.90
Consensus$563.17
High$645.00
Low$447.00
Model$664.44
Bear Case
$447
-11.3%
Consensus
$563
+11.8%
Bull Case
$645
+28.0%
Valuation Model TargetsConfidence: 39/100
Bear$-64
Base$664
Bull$966

Analyst Ratings Distribution

Breakdown of 30 published analyst recommendations for UTHR

47% hold / mixed conviction
+23
BearishBullish
Weighted analyst sentiment score based on 30 ratings
ConsensusBuy
Coverage30 Analysts
Net Score+23
Bull / Bear50% / 3%
Strong Buy00%
Buy1550%
Hold1447%
Sell13%
Strong Sell00%
Strong Buy
00%
Buy
1550%
Hold
1447%
Sell
13%
Strong Sell
00%
Recommendation Mix50% Buy · 47% Hold · 3% Sell
Buy (15)Hold (14)Sell (1)

UTHR Price Target Analysis

Updated February 28, 2026

As of February 28, 2026, United Therapeutics Corporation (UTHR) has a Wall Street consensus price target of $563.17, based on estimates from 30 covering analysts. With the stock currently trading at $503.90, this represents a potential upside of +11.8%. The company has a market capitalization of $21.99B.

Analyst price targets range from a low of $447.00 to a high of $645.00, representing a 35% spread in expectations. The median target of $581.00 aligns closely with the consensus average.

The current analyst consensus rating is Buy, with 15 analysts rating the stock as a Buy or Strong Buy,14 rating it Hold, and 1 rating it Sell or Strong Sell. The positive sentiment balance indicates moderate optimism about the stock prospects.

From a valuation perspective, UTHR trades at a trailing P/E of 18.1x and forward P/E of 16.9x. The forward PEG ratio of 0.88 suggests the stock may be undervalued relative to its growth. Analysts expect EPS to grow +7.0% over the next year.

Our proprietary valuation model, which blends historical multiples with forward estimates, suggests a base-case price target of $664.44, with bear and bull scenarios of $-64.09 and $966.45 respectively. Model confidence stands at 39/100, suggesting limited visibility into future performance.

Investment Context: Price targets represent analyst expectations for the next 12 months and should be considered alongside your own research. Targets are based on analysts' assumptions about earnings growth, margins, and market conditions which may change. For sector-specific context, view other Healthcare stocks.

Analyst Sentiment Comparison

Industry Peer Analysis
Avg Peer Upside+34.4%
Avg Forward P/E92.7x
Peers with Coverage10 / 10
CompanyMarket CapPriceTargetUpsideRatingFwd P/EAnalysts
UTHRUnited Therapeutics Corporation
$22.0B$503.90$563.17+11.8%Buy16.9x30
ZLABZai Lab Limited$21.3B$19.22$35.00+82.1%Buy—11
AMRNAmarin Corporation plc$5.7B$13.80$2.17-84.3%Hold—18
ALKSAlkermes plc$5.0B$30.10$46.00+52.8%Buy32.0x28
ADMAADMA Biologics, Inc.$3.7B$15.57$16.00+2.8%Buy16.3x9
ARQTArcutis Biotherapeutics, Inc.$3.3B$26.97$33.33+23.6%Buy73.5x12
LQDALiquidia Corporation$2.7B$31.02$50.67+63.3%Buy15.5x7
SLGLSol-Gel Technologies Ltd.$2.6B$91.68$50.00-45.5%Buy—6
MLYSMineralys Therapeutics, Inc.$2.3B$29.26$52.00+77.7%Buy—8
ARDXArdelyx, Inc.$1.6B$6.55$17.00+159.5%Buy401.8x16

Upside Potential Comparison

ARDX
+159.5%
ZLAB
+82.1%
MLYS
+77.7%
LQDA
+63.3%
ALKS
+52.8%
ARQT
+23.6%
UTHR
+11.8%
ADMA
+2.8%

See UTHR's True Return

Price is only half the story. See total return with reinvested dividends.

Launch Calculator

Is UTHR Undervalued?

See our Bear / Base / Bull DCF models and intrinsic value estimates.

View Valuation

Compare UTHR vs AGIO

See how UTHR stacks up against sector leader Agios Pharmaceuticals, Inc..

Start Comparison

Frequently Asked Questions

What is the UTHR stock price target for 2026?

United Therapeutics Corporation (UTHR) has a consensus 12-month price target of $563.17, implying 11.8% upside from $503.9. The 30 analysts covering UTHR see moderate appreciation potential.

Is UTHR a buy, sell, or hold?

UTHR has a consensus rating of "Buy" based on 30 Wall Street analysts. The rating breakdown is mixed, with 14 Hold ratings making up the largest segment. The consensus 12-month price target of $563.17 implies 11.8% upside from current levels.

Is UTHR stock overvalued or undervalued?

With a forward P/E of 16.8988x, UTHR trades at a relatively low valuation. The consensus target of $563.17 implies 11.8% appreciation, suggesting meaningful undervaluation.

How high can UTHR stock go?

The most bullish Wall Street analyst has a price target of $645 for UTHR, while the most conservative target is $447. The consensus of $563.17 represents the median expectation. Our quantitative valuation model projects a bull case target of $966 based on optimistic growth and margin assumptions. These targets typically reflect 12-month expectations.

How many analysts cover UTHR stock?

UTHR is heavily covered by Wall Street, with 30 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 15 have Buy ratings, 14 recommend Hold, and 1 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.

What is the UTHR stock forecast?

The 12-month UTHR stock forecast based on 30 Wall Street analysts shows a consensus price target of $563.17, with estimates ranging from $447 (bear case) to $645 (bull case). The median consensus rating is "Buy". Our proprietary valuation model produces a base case fair value of $664, with bear/bull scenarios of $-64/$966.

What is UTHR's fair value based on fundamentals?

Our quantitative valuation model calculates UTHR's fair value at $664 (base case), with a bear case of $-64 and bull case of $966. The model uses discounted cash flow analysis, historical growth rates, and margin mean-reversion to project FY+2 earnings, then applies an appropriate P/E multiple. The model confidence score is 39/100.

What is UTHR's forward P/E ratio?

UTHR trades at a forward P/E ratio of 16.9x based on next-twelve-months earnings estimates compared to a trailing P/E of 18.1x. The lower forward P/E indicates analysts expect earnings growth. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.

Should I buy UTHR stock?

Wall Street analysts are optimistic on UTHR, with a "Buy" consensus rating and $563.17 price target (11.8% upside). 15 of 30 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.

Why do UTHR price targets vary so much?

UTHR analyst price targets range from $447 to $645, a 35% moderate spread showing some variance in outlooks. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $563.17 consensus represents the middle ground. Our model's $-64-$966 range provides an independent fundamental perspective.

VCP Scanner

Find stocks. Verify deeply. Act with conviction.

Patterns find ideas. Fundamentals build conviction.

Data updated daily

Quick Links

  • Home
  • Screens
  • Valuation
  • Compare
  • Total Return
  • News
  • Insights
  • Methodology
  • How It Works
  • Profile

Popular Screens

  • VCP Hot
  • VCP Warm
  • Value Screens
  • Growth Screens
  • Momentum Screens
  • Technical Screens
  • Quality Screens

Community

  • Twitter
  • Get Early Access
© 2026 VCP Scanner. All rights reserved.
Made with ❤️ for investors
Not financial advice. Do your own research.